PICO_IDX,SUB_PICO_IDX,Date,Ref,PMID
15,15,1946-2018,1. Dhir V. Comparison of two different folic acid doses with methotrexate - a randomized controlled trial (FOLVARI Study). Arthritis Research & Therapy. 2015;17:156.,26063325
15,15,1946-2018,2. Morgan Sea. Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis. Ann Intern Med. 1994;121:833-41.,7978695
28,28,1946-2018,1.  Menon Nea. Comparison of Intra-articular Glucocorticoid Injections with DMARDs versus DMARDs alone in Rheumatoid Arthritis. Journal of the association of physicians of india. 2014;62:673-6.,25856933
12-14,12a,1946-2018,"1.  Mueller RBea. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine. 2019;8.",30832414
12-15,12a,1946-2018,"2. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263.",15262104
12-16,12a,1946-2018,"3. Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis care & research. 2013;65(9):1401.",23509040
12-17,12a,1946-2018,"4. Verstappen SM, Jacobs JW, Veen MJVD, Heurkens AH, Schenk Y, Borg EJt, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Annals of the Rheumatic Diseases. 2007;66(11):1443.",17519278
12-18,12a,1946-2018,"5. Fransen J. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis BMJ. 2005; 64:1294–1298.",15829574
12-19,12a,1946-2018,"6. Verstappen SMB, M. F.; et. al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis BMJ. 2010;69(6):1044-8.",19581281
12-20,13,1946-2018,1. Akdemir G. Comparison between low disease activity or das remission as treatment target in patients with early active rheumatoid arthritis. RMD Open. 2018;4(1).,29862045
21-23 55,21a,1946-2018,"1. Fleischmann R. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. The Lancet. 2017;390(10093):457.",28629665
21-23 55,21a,1946-2018,"2. Kaneko Y AT, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). BMJ. 2016;75:1917-23.",26733110
21-23 55,21a,1946-2018,"3. Dougados M. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Annals of the Rheumatic Diseases. 2014;73(5):803.",24473673
21-23 55,21a,1946-2018,"4. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Annals of the Rheumatic Diseases. 2009;68(7):1146.",18794178
21-23 55,21a,1946-2018,5. Capell HA. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Annals of the Rheumatic Diseases. 2007;66(2):235.,16926184
21-23 55,21a,1946-2018,"6. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.[Erratum appears in Arthritis Rheum. 2008 Mar;58(3):887]. Arthritis & Rheumatism. 2006;54(9):2817.",16947782
21-23 55,21a,1946-2018,7. van Riel PL. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Annals of the Rheumatic Diseases. 2006;65(11):1478.,16464988
21-23 55,21a,1946-2018,"8. Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, Riel PV. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Annals of the Rheumatic Diseases. 2005;64(1):44.",15271770
21-23 55,21a,1946-2018,9. Edwards JC. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine. 2004;350(25):2572.,15201414
21-23 55,21a,1946-2018,10. van Riel PL. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: The ADORE trial. Annals of the Rheumatic Diseases. 2008;67(8):1104.,17666447
21-23 55,21a,1946-2018,"11. Strand V, et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019;5.",31673419
21-23 55,21a,1946-2018,"12. Breedveld FA, S.; Yin, M.; et. al. Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B-Cell Levels Do Not Correlate With Clinical Response. J Clin Pharmacol. 2007;47:1119-28.",17766699
21-23 55,21a,1946-2018,"13. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis & Rheumatism. 1998;41(9):1552.",9751087
